Specifically, copy number loss of HNRNPC, METTL3, and FTO were significantly correlated with poor survival of prostate cancer, while patients with copy number gain of RBM15 and ALKBH5 had worse RFS (Figure 8A–8F). This evidence concerns the gene RBM15 and prostate carcinoma.